Search Results - kirk+gustafson

3 Results

Sort By:

Cancer Therapeutic Based on Hypoxia Inducible Factor 1 (HIF-1) Inhibitors

Abstract: Hypoxia is a characteristic of many solid tumors resulting from accelerated cellular proliferation and inadequate vascularization. HIF-1 is a transcription factor critical for maintaining cellular homeostasis in, and adaptively responding to, low oxygen environments. HIF-1 becomes activated through binding to the transcriptional co-activator...

Published: 4/22/2025 | Updated: 8/2/2023 | Inventor(s): Kirk Gustafson, Martin Schnermann, Susanna Chan, Paresma Patel, William Figg, James McMahon

Keywords(s): CANCER, Hypoxia Inhibitor, Malaria, small molecule

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics

Enhanced Cancer Chemotherapy Using the Bioactive Peptide Recifin And Its Analogues

Summary: NCI seeks research co-development partners and/or licensees for the development of recifin and its analogues as new chemosensitizing agents in adjunct therapies with topotecan, irinotecan and related chemotherapeutic agents. Description of Technology: Topoisomerase enzymes play an important role in cancer progression by controlling changes...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): Barry O'Keefe, Lauren Krumpe, Johan Rosengren, Ingrid Schroeder, Alan Bermingham, Christophe Marchand, Kirk Gustafson, Brice Wilson, Yves Pommier

Keywords(s): CANCER, Chemosensitizing Agents, CHEMOTHERAPY, Cyclic Peptide, Irinotecan TOP1, O’Keefe, Recifin, Tdp1, Topoisomerase 1 inhibitors, Topotecan, Tyrosyl-DNA Phosphodiesterase 1 Inhibitors

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Collaboration Sought > Licensing, Application > Therapeutics

Use of Cucurbitacins and Withanolides for the Treatment of Cancer

Description of Technology: Certain members of the cucurbitacin and Withanolide family have been identified that can sensitize some tumor cell lines to cell death (apoptosis) on subsequent exposure of the cells to pro-apoptotic receptor agonists (PARAS) of the TRAIL "death receptors". These PARAS include TRAIL itself, and agonist antibodies...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): Thomas Sayers, Kirk Gustafson, Karen Erickson, Alan Brooks, Curtis Henrich, Nancy Booth

Keywords(s): cucurbitacin, Immunotherapy, mapatumamab, TRAIL, withanolide

Category(s): Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing